Advisors Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.61M Buy
23,610
+2,827
+14% +$433K 0.06% 418
2025
Q4
$2.87M Buy
20,783
+726
+4% +$95.1K 0.05% 481
2025
Q3
$2.57M Sell
20,057
-1,829
-8% -$223K 0.04% 521
2025
Q2
$2.65M Sell
21,886
-2,450
-10% -$276K 0.05% 499
2025
Q1
$2.71M Sell
24,336
-1,604
-6% -$171K 0.05% 482
2024
Q4
$2.52M Buy
25,940
+1,213
+5% +$129K 0.05% 502
2024
Q3
$2.84M Sell
24,727
-2,277
-8% -$258K 0.05% 460
2024
Q2
$2.87M Buy
27,004
+2,085
+8% +$209K 0.06% 440
2024
Q1
$2.41M Buy
24,919
+2,431
+11% +$249K 0.05% 490
2023
Q4
$2.27M Buy
22,488
+2,044
+10% +$197K 0.05% 494
2023
Q3
$2.08M Sell
20,444
-138
-0.7% -$14K 0.04% 494
2023
Q2
$2.08M Buy
20,582
+2,819
+16% +$282K 0.04% 499
2023
Q1
$1.63M Sell
17,763
-1,297
-7% -$113K 0.03% 586
2022
Q4
$1.73M Sell
19,060
-667
-3% -$56.2K 0.04% 548
2022
Q3
$1.5M Sell
19,727
-3,281
-14% -$272K 0.03% 581
2022
Q2
$1.95M Buy
23,008
+690
+3% +$60.5K 0.04% 521
2022
Q1
$1.96M Sell
22,318
-1,231
-5% -$107K 0.03% 591
2021
Q4
$2.06M Sell
23,549
-697
-3% -$57.9K 0.03% 596
2021
Q3
$1.98M Sell
24,246
-51,809
-68% -$4.66M 0.03% 595
2021
Q2
$6.94M Sell
76,055
-28,175
-27% -$2.51M 0.1% 198
2021
Q1
$8.91M Sell
104,230
-23,512
-18% -$2.11M 0.14% 141
2020
Q4
$12.1M Sell
127,742
-17,543
-12% -$1.53M 0.2% 94
2020
Q3
$12.6M Buy
145,285
+6,464
+5% +$560K 0.23% 78
2020
Q2
$12.1M Buy
138,821
+6,064
+5% +$523K 0.24% 80
2020
Q1
$10.9M Buy
132,757
+14,079
+12% +$1.26M 0.26% 79
2019
Q4
$11.2M Buy
118,678
+7,695
+7% +$690K 0.2% 117
2019
Q3
$9.64M Sell
110,983
-1,188
-1% -$107K 0.18% 132
2019
Q2
$10.2M Sell
112,171
-14,170
-11% -$1.2M 0.18% 122
2019
Q1
$10.9M Buy
126,341
+4,670
+4% +$375K 0.19% 117
2018
Q4
$9.36M Buy
121,671
+1,592
+1% +$124K 0.19% 133
2018
Q3
$9.27M Sell
120,079
-5,002
-4% -$370K 0.15% 163
2018
Q2
$8.47M Buy
125,081
+3,128
+3% +$216K 0.14% 172
2018
Q1
$9.11M Buy
121,953
+2,473
+2% +$188K 0.15% 162
2017
Q4
$8.99M Sell
119,480
-2,017
-2% -$152K 0.15% 168
2017
Q3
$9.35M Sell
121,497
-6,036
-5% -$456K 0.16% 167
2017
Q2
$9.54M Buy
127,533
+8,664
+7% +$614K 0.16% 168
2017
Q1
$7.91M Sell
118,869
-8,657
-7% -$577K 0.13% 211
2016
Q4
$8.32M Sell
127,526
-4,056
-3% -$263K 0.14% 201
2016
Q3
$9.31M Sell
131,582
-18,817
-13% -$1.37M 0.15% 196
2016
Q2
$11.1M Sell
150,399
-5,150
-3% -$356K 0.18% 148
2016
Q1
$10.1M Sell
155,549
-15,164
-9% -$1.03M 0.17% 166
2015
Q4
$13.2M Sell
170,713
-4,040
-2% -$321K 0.21% 117
2015
Q3
$14.4M Buy
174,753
+415
+0.2% +$36.9K 0.23% 113
2015
Q2
$15.4M Buy
174,338
+8,895
+5% +$816K 0.21% 125
2015
Q1
$14.6M Buy
165,443
+9,530
+6% +$845K 0.19% 140
2014
Q4
$12.9M Buy
155,913
+2,374
+2% +$197K 0.17% 159
2014
Q3
$12.9M Sell
153,539
-3,048
-2% -$247K 0.18% 161
2014
Q2
$12.7M Buy
156,587
+728
+0.5% +$57.3K 0.18% 157
2014
Q1
$11.9M Buy
155,859
+1,495
+1% +$109K 0.18% 156
2013
Q4
$11.1M Buy
154,364
+3,134
+2% +$218K 0.18% 159
2013
Q3
$10.4M Buy
151,230
+7,356
+5% +$487K 0.18% 161
2013
Q2
$9.12M Buy
+143,874
New +$9.36M 0.17% 178

Other funds holding NVS

Advisors Asset Management's NVS Position: Q1 2026 in Review

Advisors Asset Management increased its Novartis (NVS) stake by 14% in Q1 2026, buying an estimated $433K and bringing the position to 23,610 shares worth $3.61M. The position accounts for 0.06% of the portfolio, ranked #418.

Advisors Asset Management first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $15.4M in Q2 2015. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Advisors Asset Management held 23,610 shares of Novartis worth $3.61M as of Q1 2026.
  • Advisors Asset Management bought 2,827 Novartis shares in Q1 2026, an estimated $433K.
  • Novartis made up 0.06% of Advisors Asset Management's portfolio in Q1 2026, its #418 holding.
  • Advisors Asset Management first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Advisors Asset Management's Novartis position peaked at $15.4M in Q2 2015.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.